Evidence map›Paper›PMID 41060413›Full record

Trial reportAnnals of hematology2025

Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study.

Xianghui Liu, Xin Xia, Lingyun Bian, Zaihong Shen, Kun Zhou, Liping Wan, Xianmin Song, Yin Tong

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xianghui LiuDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Xin XiaDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Lingyun BianDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Zaihong ShenDepartment of Hematology, Taizhou First People's Hospital, Huangyan Hospital of Wenzhou Medical University, Taizhou City, 318020, Zhejiang Province, China.
Kun ZhouDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Liping WanDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Xianmin SongDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. shongxm@139.com.
Yin TongDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. tongyin_cn2@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the efficacy of mesenchymal stem cells (MSCs) as an adjuvant therapy for cytomegalovirus (CMV) pneumonia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) through a prospective study. From June 2016 to June 2022, 43 patients were diagnosed with CMV pneumonia after allo-HSCT and received antiviral therapy, of whom 24 received MSCs infusion. The primary endpoints of the study were the cure rate and the time to cure of CMV pneumonia, and the secondary endpoint was the overall survival after CMV pneumonia. The 2-year overall survival post-pneumonia in MSCs group was significantly better than that in non-MSCs group (74% vs. 50%, p = 0.034). Cure rate of pneumonia in MSCs group was higher than that in non-MSCs group without statistical significance (79% vs. 63%, p = 0.245). Time (days) to cure in MSCs group was shorter than that in non-MSCs group without statistical significance (39[14-142] vs. 54[6-157], p = 0.765). The high mortality rate of CMV pneumonia after allo-HSCT leads to a poor prognosis. The use of MSCs improves the overall survival of CMV pneumonia. The cure rate and time to cure of pneumonia were not improved statistically. At present, there is still a lack of prospective studies on MSCs in the treatment of pneumonia after HSCT, which needs to be supplemented in the future.

Indexed as

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationMesenchymal Stem Cell TransplantationPneumonia, ViralAdolescentAdultAntiviral AgentsCytomegalovirusFemaleHumansMaleMiddle AgedProspective StudiesSurvival RateYoung AdultAntiviral AgentsAllogeneic hematopoietic stem cell transplantationCell therapyCytomegalovirus pneumoniaMesenchymal stem cells

Identifiers

PMID41060413
PMCPMC12552285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.